Search companies
EN
Login
Register
Home
StemRIM Inc.
StemRIM Inc.
4599
・
Growth Market
・
Pharmaceuticals
Follow Company
Official website
StemRIM Inc.
4599
・
Growth Market
・
Pharmaceuticals
Official website
Follow Company
Company info
Management's Perspective
Reports
StemRIM Inc.
4599
Company info
Management's Perspective
Reports
Follow Company
StemRIM Inc.
4599
Follow Company
Company info
Management's Perspective
Reports
Financials & metrics
Company overview
Segments
Business Risks
Governance & ESG
Company data
Disclosures
Financials & metrics
Company overview
Segments
Business Risks
Governance & ESG
Company data
Disclosures
Recent Disclosures
Date
Type
Title
2026-07-13
Other
StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
2026-07-13
Other
再生誘導医薬レダセムチド（HMGB1 断片ペプチド）の心筋症、陳旧性心筋梗塞、およびそれらに起因する慢性心不全を適応症とした特許登録（カナダ）のお知らせ
2026-07-08
Other
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in ,South Korea
2026-07-08
Other
栄養障害型表皮水疱症の根治治療を目的とした幹細胞遺伝子治療技術（開発コード：SR-GT1）の特許登録（韓国）のお知らせ
2026-07-06
Other
StemRIM Announces Publication of a Paper on Novel Finding about Contribution of Ectomesenchyme for Epidermal Stem Cell Formation
2026-07-06
Other
外胚葉性間葉系幹細胞による表皮幹細胞の発生機序解明に関する論文掲載のお知らせ
2026-07-04
Other
2026年臨時株主総会招集通知及び株主総会資料
2026-06-19
Other
[Delayed]Notice Regarding Recognition of Non-operating Income (Subsidy Income)
2026-06-18
Other
営業外収益（補助金収入）の計上に関するお知らせ
2026-06-17
Other
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
Disclaimer
Request
